K254084 · Smith & Nephew, Inc. · KWS · Apr 6, 2026 · Orthopedic
Device Facts
Record ID
K254084
Device Name
AETOS Shoulder System - CONCELOC Glenoids
Applicant
Smith & Nephew, Inc.
Product Code
KWS · Orthopedic
Decision Date
Apr 6, 2026
Decision
SESE
Submission Type
Traditional
Regulation
21 CFR 888.3660
Device Class
Class 2
Attributes
Therapeutic
Indications for Use
The AETOS CONCELOC Glenoids subject to this submission are intended for cemented fixation as part of an implant construct in anatomic shoulder arthroplasty for treatment of skeletally mature individuals with degenerative diseases of the glenohumeral joint.
Device Story
AETOS Shoulder System - CONCELOC Glenoids are orthopedic implants for shoulder arthroplasty; used in anatomic or reverse configurations. Anatomic configuration requires intact/reconstructable rotator cuff; reverse configuration requires functional deltoid and massive, non-repairable rotator cuff tear. System components include humeral stems, heads, glenoids, and liners. Humeral components are uncemented; glenoid components are cemented. Device provides joint mobility, stability, and pain relief. Used by orthopedic surgeons in clinical settings. Output is a reconstructed shoulder joint. Benefits include restoration of function and pain reduction in patients with degenerative joint disease, fractures, or failed prior arthroplasty.
Clinical Evidence
No clinical data. Substantial equivalence demonstrated via non-clinical bench testing, including anatomic glenoid loosening (rocking horse), pull-out analysis, post tensile attachment strength, post shear strength, high inclination fatigue, and pore morphology characterization.
Technological Characteristics
Shoulder joint metal/polymer semi-constrained cemented prosthesis. Materials consistent with predicate AETOS system. Components include glenoid (cemented), humeral stems (uncemented), and liners. Features CONCELOC porous structure. Single-use. Sterilization methods identical to predicate.
Indications for Use
Indicated for skeletally mature patients with degenerative glenohumeral joint disease requiring anatomic shoulder arthroplasty. Anatomic use requires intact/reconstructable rotator cuff. Reverse use requires functional deltoid and massive, non-repairable rotator cuff tear. Conditions include rheumatoid arthritis, non-inflammatory degenerative joint disease, functional deformity, humeral head fractures, traumatic arthritis, and revision of prior devices with sufficient bone stock.
Regulatory Classification
Identification
A shoulder joint metal/polymer semi-constrained cemented prosthesis is a device intended to be implanted to replace a shoulder joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes prostheses that have a humeral resurfacing component made of alloys, such as cobalt-chromium-molybdenum, and a glenoid resurfacing component made of ultra-high molecular weight polyethylene, and is limited to those prostheses intended for use with bone cement (§ 888.3027).
Special Controls
*Classification.* Class II. The special controls for this device are:(1) FDA's:
(i) “Use of International Standard ISO 10993 ‘Biological Evaluation of Medical Devices—Part I: Evaluation and Testing,’ ”
(ii) “510(k) Sterility Review Guidance of 2/12/90 (K90-1),”
(iii) “Guidance Document for Testing Orthopedic Implants with Modified Metallic Surfaces Apposing Bone or Bone Cement,”
(iv) “Guidance Document for the Preparation of Premarket Notification (510(k)) Application for Orthopedic Devices,” and
(v) “Guidance Document for Testing Non-articulating, ‘Mechanically Locked’ Modular Implant Components,”
(2) International Organization for Standardization's (ISO):
(i) ISO 5832-3:1996 “Implants for Surgery—Metallic Materials—Part 3: Wrought Titanium 6-aluminum 4-vandium Alloy,”
(ii) ISO 5832-4:1996 “Implants for Surgery—Metallic Materials—Part 4: Cobalt-chromium-molybdenum casting alloy,”
(iii) ISO 5832-12:1996 “Implants for Surgery—Metallic Materials—Part 12: Wrought Cobalt-chromium-molybdenum alloy,”
(iv) ISO 5833:1992 “Implants for Surgery—Acrylic Resin Cements,”
(v) ISO 5834-2:1998 “Implants for Surgery—Ultra-high Molecular Weight Polyethylene—Part 2: Moulded Forms,”
(vi) ISO 6018:1987 “Orthopaedic Implants—General Requirements for Marking, Packaging, and Labeling,” and
(vii) ISO 9001:1994 “Quality Systems—Model for Quality Assurance in Design/Development, Production, Installation, and Servicing,” and
(3) American Society for Testing and Materials':
(i) F 75-92 “Specification for Cast Cobalt-28 Chromium-6 Molybdenum Alloy for Surgical Implant Material,”
(ii) F 648-98 “Specification for Ultra-High-Molecular-Weight Polyethylene Powder and Fabricated Form for Surgical Implants,”
(iii) F 799-96 “Specification for Cobalt-28 Chromium-6 Molybdenum Alloy Forgings for Surgical Implants,”
(iv) F 1044-95 “Test Method for Shear Testing of Porous Metal Coatings,”
(v) F 1108-97 “Specification for Titanium-6 Aluminum-4 Vanadium Alloy Castings for Surgical Implants,”
(vi) F 1147-95 “Test Method for Tension Testing of Porous Metal,”
(vii) F 1378-97 “Standard Specification for Shoulder Prosthesis,” and
(viii) F 1537-94 “Specification for Wrought Cobalt-28 Chromium-6 Molybdenum Alloy for Surgical Implants.”
Porous Patella and Porous Tibia Baseplate (K211221)
Submission Summary (Full Text)
{0}
FDA U.S. FOOD & DRUG ADMINISTRATION
April 06, 2026
Smith & Nephew, Inc.
Cassidy Whipple
Senior Regulatory Affairs Specialist
7135 Goodlett Farms Pkwy.
Cordova, Tennessee 38016
Re: K254084
Trade/Device Name: AETOS Shoulder System - CONCELOC Glenoids
Regulation Number: 21 CFR 888.3660
Regulation Name: Shoulder joint metal/polymer semi-constrained cemented prosthesis
Regulatory Class: Class II
Product Code: KWS, HSD, PKC, KWT, PHX
Dated: March 9, 2026
Received: March 9, 2026
Dear Cassidy Whipple:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"
U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov
{1}
K254084 - Cassidy Whipple
Page 2
(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
{2}
K254084 - Cassidy Whipple
Page 3
Sincerely,
Joseph P. Russell -S
for: Farzana Sharmin, PhD
Assistant Director
DHT6A: Division of Joint Arthroplasty Devices
OHT6: Office of Orthopedic Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health
Enclosure
{3}
| Indications for Use | | |
| --- | --- | --- |
| Please type in the marketing application/submission number, if it is known. This
textbox will be left blank for original applications/submissions. | K254084 | ? |
| Please provide the device trade name(s). | | ? |
| AETOS Shoulder System - CONCELOC Glenoids | | |
| Please provide your Indications for Use below. | | ? |
| In Anatomic:
The AETOS Shoulder System (when used with the AETOS Humeral Meta Stems) is to be used only in
patients with an intact or reconstructable rotator cuff, where it is intended to provide increased mobility and
stability and to relieve pain.
The AETOS humeral stems (AETOS Humeral Meta Stems) and head may be used by themselves, as a
hemiarthroplasty, if the natural glenoid provides a sufficient bearing surface, or in conjunction with the
glenoid, as a total replacement.
When used with the AETOS Humeral Meta Stems, The AETOS Shoulder System is indicated for use as a
replacement of shoulder joints disabled by:
•Rheumatoid arthritis
•Non-inflammatory degenerative joint disease
•Correction of functional deformity
•Fractures of the humeral head •Traumatic arthritis
•Revision of other devices if sufficient bone stock remains
The AETOS Shoulder System (when used with AETOS Stemless Humeral Prosthesis) is to be used only in
patients with an intact or reconstructable rotator cuff.
When used with AETOS Stemless Humeral Prosthesis, the AETOS Shoulder System is indicated for
anatomic total shoulder replacement of shoulder joints disabled by:
•Non-inflammatory degenerative joint disease
•Traumatic arthritis
•Revision of other devices if sufficient bone stock remains
The coated humeral components are intended for uncemented use. The glenoid component is intended for
cemented use only.
In Reverse:
The AETOS Shoulder System, when used with AETOS Humeral Meta Stems, is indicated for use as a
replacement of shoulder joints for patients with a functional deltoid muscle and with massive and non-
repairable rotator cuff-tear with pain disabled by:
•Rheumatoid arthritis
•Non-inflammatory degenerative joint disease | | |
{4}
- Correction of functional deformity
- Fractures of the humeral head
- Traumatic arthritis
- Revision of devices if sufficient bone stock remains
The humeral liner component is indicated for use in the AETOS Shoulder System as a primary reverse total shoulder replacement and for use when converting an anatomic AETOS Shoulder System into a reverse shoulder construct. This facilitates the conversion without the removal of the humeral stem during revision surgery for patients with a functional deltoid muscle. The component is permitted to be used in the conversion from anatomic to reverse if the humeral stem is well fixed, the patient has a functional deltoid muscle; the arthroplasty is associated with a massive and non-repairable rotator cuff tear. The coated humeral stems are indicated for uncemented use. The coated glenoid base plate is intended for cementless application with the addition of screws for fixation.
Note: All implant components are single use.
Please select the types of uses (select one or both, as applicable).
☑ Prescription Use (21 CFR 801 Subpart D)
☐ Over-The-Counter Use (21 CFR 801 Subpart C)
{5}
K254084 Page 1 of 3
510(k) Summary
AETOS Shoulder System CONCELOC Glenoid
Traditional 510(k)
| Sponsor | Smith & Nephew, Inc.
Orthopedic Division
7135 Goodlett Farms Parkway
Cordova, Tennessee 38016 |
| --- | --- |
| Establishment Number | 3008744062 |
| Point of Contact | Cassidy Whipple
Senior Regulatory Specialist
512-466-1130 |
| Date | April 1, 2026 |
| Trade Name | AETOS Shoulder System CONCELOC Glenoids |
| Common Name | Shoulder Prosthesis |
| Product Code | KWS, HSD, KWT, PHX, PKC |
| Regulation | 1. Shoulder joint metal/polymer semi-constrained cemented prosthesis (21 CFR 888.3660)
2. Shoulder Joint humeral (hemi-shoulder) metallic uncemented (21 CFR 888.3690)
3. Shoulder joint metal/polymer non-constrained cemented prosthesis (21 CFR 888.3650) |
| Classification | Class II |
| Predicate Devices | AETOS Shoulder System: K240716 (Primary), K220847
Exactech Equinoxe Laser Cage Glenoid: K212356
Titan Modular Shoulder System: K142413
Porous Patella and Porous Tibia Baseplate: K211221 |
| Classification Panel | Orthopedic |
| Device Description / Intended Use | The AETOS CONCELOC Glenoids subject to this submission are intended for cemented fixation as part of an implant construct in anatomic shoulder arthroplasty for treatment of skeletally mature individuals with degenerative diseases of the glenohumeral joint. |
| Indications for Use (System) | In Anatomic: |
{6}
K254084 Page 2 of 3
| | The AETOS Shoulder System (when used with the AETOS Humeral Meta Stems) is to be used only in patients with an intact or reconstructable rotator cuff, where it is intended to provide increased mobility and stability and to relieve pain.
The AETOS humeral stems (AETOS Humeral Meta Stems) and head may be used by themselves, as a hemiarthroplasty, if the natural glenoid provides a sufficient bearing surface, or in conjunction with the glenoid, as a total replacement. When used with the AETOS Humeral Meta Stems, The AETOS Shoulder System is indicated for use as a replacement of shoulder joints disabled by:
• Rheumatoid arthritis
• Non-inflammatory degenerative joint disease
• Correction of functional deformity
• Fractures of the humeral head
• Traumatic arthritis
• Revision of other devices if sufficient bone stock remains
The AETOS Shoulder System (when used with AETOS Stemless Humeral Prosthesis) is to be used only in patients with an intact or reconstructable rotator cuff.
When used with AETOS Stemless Humeral Prosthesis, the AETOS Shoulder System is indicated for anatomic total shoulder replacement of shoulder joints disabled by:
• Non-inflammatory degenerative joint disease
• Traumatic arthritis
• Revision of other devices if sufficient bone stock remains
The coated humeral components are intended for uncemented use. The glenoid component is intended for cemented use only.
In Reverse:
The AETOS Shoulder System, when used with AETOS Humeral Meta Stems, is indicated for use as a replacement of shoulder joints for patients with a functional deltoid muscle and with massive and non-repairable rotator cuff-tear with pain disabled by:
• Rheumatoid arthritis
• Non-inflammatory degenerative joint disease
• Correction of functional deformity
• Fractures of the humeral head
• Traumatic arthritis
• Revision of devices if sufficient bone stock remains |
| --- | --- |
{7}
K254084 Page 3 of 3
| | The humeral liner component is indicated for use in the AETOS Shoulder System as a primary reverse total shoulder replacement and for use when converting an anatomic AETOS Shoulder System into a reverse shoulder construct. This facilitates the conversion without the removal of the humeral stem during revision surgery for patients with a functional deltoid muscle. The component is permitted to be used in the conversion from anatomic to reverse if the humeral stem is well fixed, the patient has a functional deltoid muscle; the arthroplasty is associated with a massive and non-repairable rotator cuff tear.
The coated humeral stems are indicated for uncemented use. The coated glenoid base plate is intended for cementless application with the addition of screws for fixation.
Note: All implant components are single use. |
| --- | --- |
| Comparison to Predicate | The proposed device is an addition of CONCELOC glenoid devices to the AETOS Shoulder System portfolio. |
| Nonclinical Performance Data | Comparison to the predicate demonstrating the CONCELOC glenoid has no effect on the following non-clinical performance tests.
• Anatomic Glenoid Loosening (Rocking Horse)
• Anatomic Pull-Out Analysis
• Post Tensile Attachment Strength
• Post Shear Strength
• High Inclination Fatigue
• Pore Morphology Characterization |
| Clinical Performance Data | Clinical performance data were not necessary to demonstrate substantial equivalence of the subject device. |
| Conclusion | Substantial equivalence of the AETOS Shoulder System CONCELOC Glenoid to cited predicates can be demonstrated based on the following:
• The subject and predicate devices have the same intended use and the same Indications for Use.
• The subject and predicate devices share the same functional and technological characteristics via the same operational principles.
• The subject and predicate devices are made from the same materials and packaged and sterilized using the same methods.
Evaluation supports that differences between subject and predicate devices do not raise different questions of safety and effectiveness. As a result, Smith & Nephew concludes the subject AETOS Shoulder System CONCELOC Glenoids are substantially equivalent to cited predicate device. |
